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Summary
The type I interferons (IFNs) are pleiotropic cytokines
that regulatemany different cellular functions. Thema-
jor signaling pathway activated by type I IFNs involves
sequential phosphorylation of the tyrosine residues
of the Janus kinase (JAK) and signal transducers
and activators of transcription (STAT) proteins, pro-
viding the primarymechanism throughwhich gene ex-
pression is induced. Recent work has shown that the
responses are quite complex, as shown by different
responses to specific subtypes of type I IFN, activation
of kinases in addition to JAKs, patterns of activation
of all seven STATs in different cells, and activation of
transcription factors other than STATs. The type I
IFNs use this complexity to regulate many different
biological functions in different types of cells, by acti-
vating different specific signals and patterns of gene
expression.
Introduction
The type I interferons (IFNs) include IFN-a, IFN-b, IFN-u,
IFN-t, IFN-d, IFN-k, and IFN-3. The predominant forms
are IFN-a, of which there are 12 separate proteins in hu-
mans, and a single IFN-b (Pestka et al., 2004). All type I
IFNs are genetically and structurally very similar: they
all lack introns, are located on the short arm of chromo-
some 9, and utilize the same receptor subunits (Novick
et al., 1994). Interestingly, different type I IFNs stimulate
different antiviral, antiproliferative, and clinical re-
sponses (Foster et al., 1996) and are likely to stimulate
different immunoregulatory responses as well. The re-
sponses to type I IFNs are initiated by their interactions
with a specific cell-surface receptor, which has an extra-
cellular ligand binding domain and an intracellular ki-
nase domain, activated after ligand-induced dimeriza-
tion (Darnell et al., 1994). The receptor has two chains,
IFNAR1 and IFNAR2c (a specific splice variant). Both
are necessary for most functions and, in the absence
of either, there is no high-affinity ligand binding and little
biological effect. Each receptor subunit binds constitu-
tively to a single specific member of the Janus kinase
(JAK) family: IFNAR1 to tyrosine kinase 2 (TYK2) and
IFNAR2 to JAK1. Ligand binding induces the phosphor-
ylation of JAK1, TYK2, intracellular tyrosine residues of
each receptor chain and signal transducers, and activa-
tors of transcription (STATs). Activated STATs dimerize,
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cleus to induce the expression of interferon-stimulated
genes (ISGs) (Stark et al., 1998). In many cells, type I
IFNs activate a major transcription factor, IFN-stimu-
lated gene factor 3 (ISGF3), a complex of phosphory-
lated STAT1, STAT2, and unphosphorylated interferon
regulatory factor 9 (IRF-9, formerly p48), which binds
to IFN-stimulated response elements (ISREs) present
in the promoters of many ISGs. Type I IFNs can activate
all seven STAT family members in different cell types,
leading to the formation of many hetero- and homodimer
pairs, as well as complexes with other transcription
factors.
Interferon Receptor Function
All the effects of type I IFN depend on the receptor, but
most of the fine mapping of the biochemical events
required for signaling has been done in the context of
activating antiviral functions. The two subunits of the re-
ceptor have distinct functions in signaling. Truncations
of the cytoplasmic domain of IFNAR1 lead to variations
in the antiviral response (Gibbs et al., 1996; Basu et al.,
1998). Chimeras of the intracellular domain of IFNAR1
and the extracellular domain of CD4, when crosslinked
by anti-CD4, activate the TYK2-dependent phosphory-
lation of IFNAR1 (Krishnan et al., 1996), but is not
sufficient to activate STATs. With human IFNAR2c ex-
pressed in murine cells, human IFN-a2 and IFN-b were
shown to require distinct intracytoplasmic regions to
induce an antiviral response (Domanski et al., 1998).
However, the expression of IFNAR2c mutants, which
are truncated in the cytoplasmic domain, in human
U5A cells that lack IFNAR2c, did not yield similar results,
possibly because of cell-type differences (Wagner et al.,
2002). Substitution of any one of the seven cytoplasmic
tyrosines (at positions 269, 306, 316, 318, 337, 411, and
512) with phenylalanine had no effect on IFN-dependent
signaling (Wagner et al., 2002). However, mutation of all
seven tyrosines to phenylalanines (mutant 7F) rendered
the receptor unresponsive to type I IFNs for STAT acti-
vation, gene expression, and antiproliferative and antivi-
ral effects, although JAK1 phosphorylation could still be
detected (Wagner et al., 2002). Cells (FF) carrying the
double mutant of IFNAR2c, Y337F and Y512F, are unre-
sponsive to IFN-b. It is possible that the other tyrosine
residues of IFNAR2c may be needed to activate kinases
other than JAKs and transcription factors other than
STATs. There may also be cell type-specific differences
in receptor composition or in the expression of cell-
surface proteins that modify receptor function, as sug-
gested by the finding of Overall et al. (1992) that IFN-a in-
teracts differently with lymphoid compared to epithelial
cells. These differences are likely to be important be-
cause the biological actions of type I IFNs include differ-
ent ranges of subtypes in different cells.
The responses to type I IFNs are negatively regulated
by several mechanisms, some of which involve the
receptor subunits, including dephosphorylation of the
receptor, the JAKs, and the STATs, inhibition of STAT
functions in the nucleus by protein inhibitors of activated
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the interferon-induced suppressor of cytokine signaling
1 (SOCS1) on the receptor (Greenhalgh and Hilton, 2001;
Yamada et al., 2003; Shuai and Liu, 2005; Fenner et al.,
2006). SOCS1 regulates the immune response to infec-
tion through its association with IFNAR1 but not IFNAR2
(Fenner et al., 2006). Also, UBP43 has recently been
added to the list of inhibitors that function at the level
of the receptor (Malakhova et al., 2006). The fascinating
complexity of negative regulation of IFN-dependent
signaling has been reviewed extensively and recently
(Shuai and Liu, 2005) and therefore will not be discussed
further here.
Differential Responses to Different
Type I IFN Subtypes
Differential responses are very likely to be important in
mediating specific IFN-dependent effects on various
tissues or cells. IFN-a2 is used clinically to treat various
forms of leukemia, T cell lymphoma, malignant mela-
noma, renal cell carcinoma, and hepatitis B and C (Bor-
den, 1998; Platanias, 2005), and IFN-b is used to treat
relapsing-remitting multiple sclerosis (Rudick et al.,
2004). IFN-b generates a more stable signaling complex
than IFN-a2 because IFNAR2c coimmunoprecipitates
with IFNAR1 in cells stimulated with IFN-b but not IFN-
a2 (Abramovich et al., 1994; Croze et al., 1996; Platanias
et al., 1994). Studies with alanine substitutions of the ex-
tracellular domain of IFNAR2c reveal that different type I
IFNs interact differently with the two receptor subunits
(Lewerenz et al., 1998). U1A cells (lacking TYK2) respond
to IFN-b but not IFN-a2 or IFN-a8 (Pellegrini et al., 1989;
Gauzzi et al., 1997; Platis and Foster, 2003). In addition
to its role as a kinase, TYK2 is a structural component
that helps to stabilize the receptor complex and is par-
ticularly important for binding of IFN-a.
Because different subtypes of type I IFN activate the
same cell-surface receptor complex to mediate variable
responses, it seems likely that differences in critical
amino acid residues among the different type I IFN sub-
types result somehow in different ligand-receptor inter-
actions and downstream responses (Deonarain et al.,
2002). Indeed, there is a distinct binding site on IFNAR1
for IFN-b and some hybrid IFN-a subtypes (Platis and
Foster, 2003). IFN-b also forms complexes with the ex-
tracellular domains of lipid bound IFNAR2c or IFNAR1
with higher affinity than IFN-a2 (Lamken et al., 2004).
These findings may explain why gene-array studies
with fibrosarcoma cells, primary vascular endothelial
cells, and melanoma cells have uniformly found that
ISGs are more strongly induced by IFN-b than by IFN-a
(da Silva et al., 2002; de Veer et al., 2001; Der et al.,
1998; Leaman et al., 2003).
Selective effects of IFN-b but not IFN-a have been re-
ported in different cell types. The effects of IFN-a2 or
IFN-bon the differentiation of human monocytes into os-
teoclasts reveal that IFN-b is 100 times more potent than
IFN-a2 (Coelho et al., 2005). IFN-b but not IFN-a selec-
tively induces CXCL11 gene in human fibrosarcoma
and astrocytoma cells (Rani et al., 1996). ISGF3 forma-
tion is induced equally well by both type I IFNs, indicat-
ing that additional signaling components are necessary
to induce CXCL11 (Rani et al., 1999, 2001, 2002). Tumor
necrosis factor-related apoptosis-inducing ligand(TRAIL) mRNA is also preferentially induced by IFN-b
compared to IFN-a in melanoma cell lines sensitive to
apoptosis and in fibrosarcoma cells (Rani and Ransoh-
off, 2005; Chawla-Sarkar et al., 2001). It is interesting in
this regard that different type I IFNs vary in the activation
of mitogen-activated protein kinases (MAPKs) in J2E
leukemia cells immortalized at the proerythroblast-ba-
sophilic erythroblast stage. Whereas all type I IFNs stud-
ied activated ERK1 and ERK2, phosphorylation of JNK is
detected only after IFN-b stimulation and not after stim-
ulation with IFN-a1, IFN-a2, IFN-a4, IFN-a5, IFN-a6, or
IFN-a9 (Cull et al., 2003). Reciprocally, p38 MAPK is ac-
tivated in J2E cells by all of the above IFN-a subtypes,
but not by IFN-b. Both IFN-a2b and IFN-b activated
ERK1 and ERK2 in hepatocellular carcinoma cells, but
only IFN-b activated the kinase AKT (Matsumoto et al.,
2005). Because different type I IFNs vary in their ability
to activate signaling pathways (in addition to JAK-
STAT) in certain cell types, they are likely to induce dif-
ferent genes. For example, in EW-7 Ewing’s sarcoma
cells, the selective apoptosis induced by IFN-b but not
IFN-a is caused by the induction of IRF-1 and cas-
pase-7 (Sanceau et al., 2000). Also, in IL-7-dependent
pro-B cells, IFN-b but not IFN-a induces apoptosis,
which seems to depend on the activation of TYK2 and
STAT3 (Gamero et al., 2006) and is independent of phos-
phatidyl inositol 3 kinase (PI3K) and STAT1 activation
(Gongora et al., 2000). Systematic studies comparing
the activation of additional pathways by various type I
IFNs, especially IFN-a and IFN-b, in different cell types
are warranted to explain the different outcomes. Under-
standing the mechanisms of action of the different type I
IFNs in more detail would help greatly to be able to use
them most effectively as therapeutic agents in settings
where a defined cell type is to be targeted.
Activation of Kinases Other than JAKs
JAK-STAT signaling alone is not sufficient to explain all
the biological effects of type I IFNs. The PI3K and p38 ki-
nase pathways have emerged as critical additional com-
ponents of IFN-induced signal transduction, and their
roles in IFN signaling and IFN-mediated biological ef-
fects have been summarized in recent reviews (Kaur
et al., 2005; Katsoulidis et al., 2005). PI3K designates
a family of bifunctional kinases that phosphorylate lipid-
or protein-signaling intermediates. The p110 catalytic
subunits of PI3K are complexed with regulatory p85
subunits, which can associate with receptor tyrosine ki-
nases directly, by interaction of their SH2 domains with
phosphotyrosine residues, or indirectly, via the YXXM
consensus sequence to bind to an adaptor molecule
(Kaur et al., 2005). AKT (also known as protein kinase
B, or PKB) is a major downstream effector of PI3K, and
this pathway mediates antiapoptotic events in response
to growth factors and cytokines. It is well established
that the PI3K pathway is activated in response to type I
IFNs, although the mechanism of activation is different
in different cell types. In Daudi cells, phosphorylated
STAT3 provides a docking site that allows PI3K to be
activated by IFN-a (Pfeffer et al., 1997). PI3K activity in
IFN-a-treated cells correlated with insulin receptor sub-
strate 1 (IRS-1) phosphorylation and required the pres-
ence of JAK1 or TYK2 (Burfoot et al., 1997). In various
hematopoietic cells, type I IFNs rapidly phosphorylate
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STAT pathway (Platanias et al., 1996; Uddin et al.,
1997). The p85 subunit of PI3K is constitutively associ-
ated with IFNAR1 and is activated by type I IFN indepen-
dently of TYK2 catalytic activity (Rani et al., 1999). In fi-
brosarcoma cells, the activation of PI3K by IFN-b leads
to AKT phosphorylation (Rani et al., 2002). PI3K signaling
is also required for IFN-b-induced phosphorylation of the
transactivation domain of the p65 subunit of NF-kB and
consequent transcription of CXCL11 (Rani et al., 2001,
2002). Specific tyrosine residues of the type I IFN recep-
tor may be required to dock unknown adaptor or signal-
ing molecules, leading to the activation of PI3K. It is
possible that the specific accessory signaling molecules
activated in a particular cell type depend on the cell type-
specific expression of adaptor molecules.
The functional role of PI3K in IFN-dependent signaling
in various cells is yet to be explained. PI3K can activate
death or survival pathways, depending on the cell type
and type of IFN. However, the downstream effectors of
PI3K in type I IFN-dependent signaling are beginning
to be identified. Incubation of neutrophils with IFN-bpro-
tects them from apoptosis through a pathway that re-
quires PI3K and NF-kB (Wang et al., 2003). IFN-b pro-
motes the survival of primary astrocytes by activating
PI3K-AKT signaling (Barca et al., 2003). IFN-a promotes
the survival of primary B cells through a PI3K-dependent
pathway (Ruuth et al., 2001). Maximum transcriptional
activation of STAT 1 and STAT3 requires phosphoryla-
tion of serine residues at position 727 in their C-terminal
domains, and PI3K may be the kinase responsible (Wen
et al., 1995). An intact PI3K-mTOR pathway is necessary
for IFN-a to induce apoptosis in myeloma cells, because
activation of the JAK-STAT pathway alone is insufficient
(Thyrell et al., 2004).
P38 is a serine-threonine kinase that is activated in re-
sponse to type I IFNs (Uddin et al., 1999), and increasing
evidence suggests that it plays a role in mediating or
modulating IFN-dependent responses. In Hela S3 cells,
type I IFN activates p38, leads to the phosphorylation of
S727 of STAT1, and is required for the antiviral response
and ISRE-dependent gene expression (Goh et al., 1999).
However, the activation of p38 by type I IFN in hemato-
poietic cell lines such as MOLT-4, although required for
ISRE-dependent gene expression, does not play a role
in phosphorylating S727 of STAT1 (Uddin et al., 1999,
2000; Li et al., 2004). In these cells, the PKC-d activated
by type I IFNs is required to phosphorylate S727 (Uddin
et al., 2002). It is not clear which of the four isoforms of
PKC-d are activated in response to type I IFNs or how
they are regulated, although MAPKs 3 and 6 have been
reported to be required for full p38 activation (Li et al.,
2005). Activated p38 can, directly or indirectly, activate
multiple downstream substrates and effector pathways
(Katsoulidis et al., 2005). Several dual-specificity MAPK
phosphatases have also been shown to regulate the
p38 pathway (Farooq and Zhou, 2004).
Chemical or genetic inactivation of p38 selectively
blocks the induction of the CXCL11 and TNFSF10 (en-
coding TRAIL) genes by IFN-b (Rani and Ransohoff,
2005). The induction of CXCL10 (encoding IP-10) by
IFN-b depends on the activation of p38 in primary leuko-
cytes (Hilkens et al., 2003). In hematopoietic cells, the
GTPase Rac I is a substrate for the guanine-nucleotideexchange activity of VAV, which is phosphorylated by
TYK2, leading to activation of downstream kinases
that phosphorylate p38 (Li et al., 2004; Platanias and
Sweet, 1994; Uddin et al., 2000). However, in nonhema-
topoietic cells, it is not known whether VAV is phosphor-
ylated on tyrosine or if it provides an SH2 site for docking
phosphotyrosines to the IFN receptor. In summary, it is
well accepted that, in addition to the JAKs, several
different kinases are activated in response to IFNs and
one can safely predict that the cell type-specific expres-
sion of different substrates of these kinases participate
in cell type-specific responses.
Differential Activation of STATs
in Different Cell Types
Type I IFNs are unique among all cytokines in that they
can activate all seven known STATs. All the STATs
have SH2 domains, which allow them to dock to phos-
phorylated tyrosine residues of the receptors (Darnell,
1997; Domanski et al., 1998). Interestingly, many differ-
ent homodimer or heterodimer complexes can form in
response to type I IFN action (reviewed in Brierley and
Fish, 2005; Platanias, 2005). Studies with intracellular
flow cytometry and antibodies specific for each phos-
phorylated STAT have revealed major differences in
the activation of STAT1, STAT3, and STAT5 in response
to IFN-b in the monocytes, B cells, and CD4+ and CD8+ T
cells present in human whole blood (our unpublished
data).
The differential and unique STAT activation patterns
in blood cells are very likely to drive different biological
functions. Indeed, IFN-a-induced activation of STAT1
and STAT3 may be related to the induction of the T-bet
transcription factor and IL-12Rb2 in naive human T cells,
essential for differentiation to the T helper 1 (Th1) pheno-
type (Hibbert et al., 2003). Activation of STAT1, STAT3,
and STAT4 by IFN-a in primary human T cells leads to up-
regulation of the IL2RA, MYC, and PIM1 genes, and all
of the corresponding proteins are known to be involved
in the proliferation or survival of T cells (Matikainen
et al., 1999). Stimulation of CD8+ T cells by antigens
plus costimulatory ligands leads to proliferation but lim-
ited clonal expansion and survival. Type I IFN can pro-
vide a third signal to mouse CD8+ T cells by activating
STAT4 and thus can stimulate survival, cytolytic func-
tion, and production of IFN-g in this T cell subset (Curt-
singer et al., 2005). Expansion of CD8+ T cells is of utmost
importance during viral infection, and only CD8+ T cells
with low STAT1 expression will proliferate and produce
IFN-g in a STAT4-dependent manner in response to
type I IFN (Garcia-Sastre and Biron, 2006; Gil et al., 2006).
In activated mouse CD4+ T cells, type I IFNs trigger
two opposing pathways (activation of STAT1 versus
STAT3 and STAT5), where STAT1 activates a dominant
signaling cascade related to an antiproliferative and
proapoptotic response (Tanabe et al., 2005). The mech-
anism by which activated STAT1 induces this effect in T
cells is not known, but in Ewing’s sarcoma cells, the ap-
optotic effects are mediated through the induction of
IRF-1 and the activation of caspase-7 (Sanceau et al.,
2000) or the induction of TRAIL and the cell-surface
death-signaling pathway (Choi et al., 2003). In contrast,
activation of both STAT3 and STAT5 is needed for type
I IFN to generate an antiapoptotic response in mouse
Immunity
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largely dependent on the activation of STAT3 (Tanabe
et al., 2005). Enhancement of survival and proliferation
in CD4+ T cells might occur only when STAT1 expression
is relatively low. Similarly, type I IFN stimulates prolifer-
ation only in STAT1- or STAT2-deficient CD4+ and CD8+
T cells, indicating that signaling through ISGF3 or a
STAT1-STAT2 heterodimer results in an antiproliferative
effect (Gimeno et al., 2005). In this study, the proliferative
effect of type I IFNs in thymocytes was dependent on
STAT3 in the absence of STATs 1 or 2, but the use of dif-
ferent T cells (thymocytes versus CD4+ T cells) and differ-
ent additional stimuli (phorbol 12,13-dibutyrate and IL-2
versus antigen-presenting cells) might account for the
different outcomes (Tanabe et al., 2005). Nevertheless,
both studies suggest that type I IFNs stimulate prolifera-
tion of both CD4+ and CD8+ T cells when STAT1 expres-
sion is relatively low. It has been shown that type I IFNs
keep activated T cells alive, and this effect may be inde-
pendent of STAT1 activation because IFN-g, which acti-
vates STAT1 predominantly, does not enhance T cell
survival (Marrack et al., 1999). Because T cell receptor-
activated T cells cannot phosphorylate STAT1 (Van De
Wiele et al., 2004), we speculate that other STATs can still
be activated, which might explain why type I IFN can
function as a survival factor for these cells.
In contrast to the above study, activation of STAT3 is
required for the apoptotic actions of IFN-b in primary
murine pro-B cells (Gamero et al., 2006). Of note, IFN-
b-mediated growth inhibition of these cells does not re-
quire the expression of STAT1 but does require induction
of the protein Daxx (Gongora et al., 2001). It is likely that
STAT3 activation is necessary for the induction of Daxx
by type I IFNs (Shimoda et al., 2002; Gamero et al.,
2006). Interestingly, a type I IFN-resistant subclone of
human Daudi B cells becomes sensitive again after
transfection with STAT3, because the antiviral and anti-
proliferative action of type I IFN is restored (Yang et al.,
1998). In Daudi cells, IFN-a activates STAT5 and
STAT6, in addition to STAT1, STAT2, and STAT3 (Fas-
ler-Kan et al., 1998). Only B cells seem to be able to acti-
vate STAT6 in response to IFN-a, leading to the formation
of unique STAT2-STAT6 dimers that bind to GAS ele-
ments and to an ISGF3-like complex of STAT2-STAT6-
IRF-9, which binds to ISREs (Gupta et al., 1999). It is likely
that these specific transcription factors allow type I IFN
to induce B cell-specific genes, although these have
not yet been identified. However, a Daudi subclone resis-
tant to IFN-a does not activate STAT6, suggesting that
complexes containing STAT6 may play a more general
role in the gene activation that is necessary for the antivi-
ral and antiproliferative effects of type I IFN (Gupta et al.,
1999).
In promonocytic cell lines, IFN-a activates STAT1,
STAT3, and STAT5 (Ho and Ivashkiv, 2006; Meinke
et al., 1996). IFN-a-activated STAT3 inhibited the
STAT1-dependent expression of the inflammatory che-
mokine genes CXCL9 (encoding MIG) and CXCL10,
whereas ISGF3-dependent gene induction was not af-
fected (Ho and Ivashkiv, 2006). STAT3 does not hinder
STAT1 activation or nuclear translocation, but seques-
ters STAT1 into STAT1-STAT3 heterodimers, suppress-
ing in this manner STAT1 homodimer formation and con-
comitant gene activation (Ho and Ivashkiv, 2006). Theseresults suggest that the relative amounts of STATs 1 and
3 present in monocytes at the time of stimulation with
type I IFN largely determine the outcome in terms of
gene expression. Although the activation of STAT4 by
type I IFN was thought initially to occur only in T and
NK cells, STAT4 activation is also shown in endothelial
cells, activated monocytes, and dendritic cells (DCs)
(Frucht et al., 2000).
IFN-aactivates STAT1 and STAT4 strongly, STAT3 and
STAT5 weakly, and STAT6 not at all in NK cell lines and
primary NK cells (Matikainen et al., 2001; Nguyen et al.,
2002; Liang et al., 2003). Activation of STAT1 by IFN-a
regulates the cytotoxicity of NK cells by inducing the
cytolytic effectors FasL and perforin (Nguyen et al.,
2002; Liang et al., 2003). The survival of proliferating NK
cells is STAT4 independent, in contrast to the survival
of CD8+ T cells, but requires the type I IFN-dependent,
STAT1-dependent induction of IL-15 (Nguyen et al.,
2002). Activation of STAT4 by IFN-a results in IFN-g pro-
duction by NK cells, similar to events in CD8+ T cells
(Matikainen et al., 2001). IFN-a activates STATs 1 and 3
but not STAT5 in human neutrophils and has an antia-
poptotic effect in neutrophils by upregulating cellular
inhibitor of apoptosis 2 (cIAP2) expression, which is de-
pendent on STAT3 activation (Sakamoto et al., 2005).
Thus, similarly to CD4+ T cells, but in contrast to B cells,
the activation of STAT3 by type I IFN delays apoptosis in
neutrophils, although it is not certain whether the mech-
anism in T cells and neutrophils is the same.
IFN-a activates STAT1, STAT2, STAT3, and STAT5 in
human primary hepatocytes, resulting in the upregula-
tion of 44 genes (including antiviral, tumor suppressor,
and proapoptotic genes) by more than 2-fold, and
downregulates 9 genes (e.g., MYC) by 50% or more (Ra-
daeva et al., 2002). In human umbilical vascular endo-
thelial cells (HUVEC), IFN-a activates STAT1, STAT2,
STAT3, STAT4, and STAT5 (Gomez and Reich, 2003;
Torpey et al., 2004). STAT4-mediated induction of
SOCS3 and MCP-1 was observed, suggesting that
IFN-a may modulate the proinflammatory behavior of
these cells (Torpey et al., 2004). The growth of HUVEC,
primary human fibroblasts, and smooth muscle cells are
all stimulated by IFN-a (Gomez and Reich, 2003). Via
DNA microarray analyses, it was shown that, in HUVEC,
IFN-a induced the transcription of genes involved in cel-
lular proliferation, probably related to the activation of
STAT3 and STAT5 (Gomez and Reich, 2003). Interest-
ingly, IFN-a induces the activation of STAT5 in mela-
noma cells and, similarly, in other cells overexpressing
STAT5, this activation contributes to resistance to IFN-
a-mediated inhibition of growth (Wellbrock et al., 2005).
In summary, different cell subsets utilize different pat-
terns of cell type-specific STAT activation in response to
type I IFNs. However, much more research is needed to
understand how and why different cell subsets activate
different STATs and also to comprehend fully how the
activation of each specific STAT in each specific cell
type leads to the induction of specific genes, thus con-
tributing to specific biological responses.
Priming: How Prior Exposure to Other Cytokines
Affects Responses to Type I IFNs
Exciting new data have emerged indicating that, espe-
cially during inflammation, pre-exposure to certain
Review
365cytokines profoundly changes how cells respond sub-
sequently to type I IFNs. The microenvironment of the
cells is also likely to be important, through specific
cell-cell contacts. One obvious mechanism through
which priming can affect type I IFN-dependent signaling
is by enhancing the expression or activity of specific
transcription factors. For instance, priming with IFN-g
increased the concentrations of all three ISGF3 compo-
nents (STAT1, STAT2, and IRF-9), resulting in increased
responsiveness of IFN-resistant melanoma cells to type
I IFNs (Wong et al., 1998). Likewise, IL-12 pretreatment
of PBMC or melanoma cells enhances the expression
of ISGF3 components by inducing the production of
IFN-g and potentiates IFN-a-induced signaling in vivo
to the extent that mice can be cured of an otherwise fatal
tumor burden (Lesinski et al., 2004). It is well established
that the biological role of STAT1 is proinflammatory,
antiproliferative, and proapoptotic and thus opposite
from the roles of STAT3 and STAT5. STAT1 seems to
compete with STAT3 in CD4+ T cells and monocytes (Ta-
nabe et al., 2005; Ho and Ivashkiv, 2006), STAT4 in CD8+
T cells (Garcia-Sastre and Biron, 2006), and STAT5 in
CD4+ T cells and melanoma cells (Tanabe et al., 2005;
Wellbrock et al., 2005). Changes in the concentration
of STAT1 compared to those of STAT3, STAT4, or
STAT5 can dramatically change the pattern of gene ac-
tivation. Stimulation with IL-6 increases the expression
of STAT3 (Yang et al., 2005), and therefore one can pre-
dict that priming with IL-6 would enhance STAT3 activa-
tion in response to type I IFNs. Of note, monocytes do
not express STAT4 constitutively, but pre-exposure
of monocytes or DCs to IFN-g or LPS leads to high
amounts of STAT4, and subsequent stimulation with
IFN-a will then activate STAT4 (Frucht et al., 2000). It is
not known whether the increase of STAT4 expression
in response to IFN-g or LPS is a general phenomenon
or whether it occurs only in antigen-presenting cells. In
contrast, increased STAT1 expression 16 hr after IFN-g
stimulation seems to happen in most cell types, leading
to competition with the other STATs at the level of acti-
vation at type I IFN receptors or because alternative
STAT dimers are formed (for example, STAT1-3 instead
of STAT1-1; Ho and Ivashkiv, 2006).
Priming with very low concentrations of IFN-g for 2
days increases total STAT1 expression in primary hu-
man monocytes and also leads to increased tyrosine
phosphorylation (PY) of STAT1 in response to IFN-a
(Hu et al., 2002). Priming with IFN-g of human Hep3B
hepatoma cells for 1 day also increases STAT1 activa-
tion by IFN-a (Radaeva et al., 2004). In contrast, priming
with IFN-g of Hep3B cells for 3–6 days decreases PY-
STAT1 and totally abolishes the activation of STAT2
and STAT3 by IFN-a, despite normal STAT3 expression
and increased expression of STAT1 and STAT2 (Ra-
daeva et al., 2004). This negative inhibitory effect of
long-term priming with IFN-g on subsequent type I
IFN-dependent signaling in Hep3B cells cannot be ex-
plained by increased amounts of SOCS1. Of note, over-
expression of wild-type STAT1 in Hep3B cells only di-
minished the activation of STAT1, STAT2, and STAT3
by IFN-a but increased STAT1 activation by IFN-g (Ra-
daeva et al., 2004). The inhibition of the activation of
STAT1, STAT2, and STAT3 by IFN-a after long-term
priming with IFN-g might be explained by increased ex-pression of a negative inhibitor of JAK-STAT signaling
other than SOCS1. Interestingly, prior administration of
IL-1b in vivo attenuates the subsequent induction by
type I IFN of PY-STAT1 in the liver but not in the spleen
(Tian et al., 2000), suggesting that priming with certain
cytokines might affect type I IFN-dependent signaling
in a cell type-specific manner. Pre-exposure of human
HepG2 hepatoma cells to IL-1b diminishes the amount
of PY-STAT1 induced by type I IFN without affecting
the amount of total STAT1 (Tian et al., 2000). This inhib-
itory effect could be reversed by pretreatment with pro-
teosome inhibitors, suggesting that IL-1b attenuates
type I IFN-induced STAT1 activation (Tian et al., 2000).
Because the inhibitory priming effect of IL-1b is very
rapid (seen after 30 and 60 min, but not after 12 or 24
hr), IL-1bmight promote proteosome-dependent degra-
dation of an unknown protein, followed by the release of
an inhibitory protein, possibly a protein tyrosine phos-
phatase (PTP). Notably, pre-exposure of primary human
fibroblasts or monocytes to IFN-b for 16 hr, followed by
washing and subsequent restimulation with IFN-b for 30
min, results in severely reduced activation of STAT2 and
totally abrogates the activation of STAT1, leading to di-
minished activation of specific genes (Sakamoto et al.,
2004). The inhibitory effect of priming with IFN-b, leading
to lack of STAT1 tyrosine phosphorylation and DNA
binding after IFN-b restimulation, is due to increased ac-
tivity of the protein tyrosine phosphatase Tc-PTP. Thus,
priming with IL-1b and IFN-b both have an inhibitory ef-
fect on type I IFN-dependent signaling by activating a
PTP (although at different points in time), and this effect
might be cell type specific.
As discussed above, priming with IFN-g for 1 day re-
sults in increased PY-STAT1 after subsequent stimula-
tion with IFN-a, but priming with IFN-g for 3 days or lon-
ger leads to decreased IFN-a-induced STAT1 activation
through an as-yet-unknown mechanism. A recent study
shows that priming with IFN-g for 2 days or less can in-
crease IFN-a-induced STAT1 activation in macrophages
by a mechanism distinct from an increase of total STAT1
amounts (Tassiulas et al., 2004). Enhanced IFN-a-in-
duced STAT1 activation and concomitant gain of proin-
flammatory functions are dependent on the tyrosine
kinase Syk and on the adaptor proteins that activate
Syk through immunoreceptor tyrosine activation motifs
(ITAMs). Although not yet completely clear, these results
suggest a mechanism in which crosstalk between cyto-
kine- and ITAM-dependent signaling pathways regu-
lates the responses of macrophages (and perhaps other
cell subsets) to type I IFNs. Interestingly, IFN-g and IL-6
cannot signal properly in the absence of IFNARs, sug-
gesting constitutive crosstalk between these cytokine
receptors. Low amounts of IFN-b are always present
and result in interaction of IFNAR1 with IFNGR2 and
gp130 in caveolar domains of the plasma membrane
(Taniguchi and Takaoka, 2001). The associated IFNAR1
may provide an additional docking site that promotes
the dimerization of STATs and concomitant increases
in DNA binding and transcription in response to IFN-g
or IL-6, or transphosphorylation of the receptors may
lead to enhanced STAT activation (reviewed by Tanigu-
chi and Takaoka, 2001; Ivashkiv, 2003). Of note, all of the
data of Taniguchi and Takaoka (2001) were generated
with mouse cells, and it is not known whether the
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man cells. Furthermore, priming with type I IFN influ-
ences normal IL-6 and IFN-g signaling pathways, but it
is not certain whether, vice versa, priming with IFN-g or
IL-6 influences type I IFN-dependent signaling through
receptor crosstalk.
In summary, the data show that priming can positively
or negatively change the quantity and quality of signal
transduction by type I IFNs, and several possible mech-
anisms have been described. Therefore, the nature of the
type I IFN response can be altered or reprogrammed.
This flexibility is certain to play an important role during
infection and inflammation, because in both situations
cells are exposed repeatedly to bursts of cytokine re-
lease. It remains to be established whether type I IFN-in-
duced signaling can be altered similarly in various blood
cell subsets after priming, especially with IFN-b, IL-1b, or
IFN-g. More work is also needed to determine how long
the effects of priming last.
Activation of Transcription Factors
Other than STATs
Type I IFNs differentially activate STATs 1–6 in different
cell subsets by activating JAK1 and TYK2. However, ad-
ditional transcription factors are activated as well. In re-
sponse to type I IFNs, PI3K, ERK, and p38 are activated
and are involved in the activation of NF-kB, AP-1, and
(possibly) PU.1, respectively. These transcription fac-
tors induce genes either independently or collabora-
tively with STAT family members. That additional tran-
scription factors may collaborate with STAT1 is also
suggested by a recent study showing that newly identi-
fied ISGs on chromosome 22 have nonconserved STAT1
binding sites, because these STAT1-dependent IFN-a-
induced promoters are not occupied by IFN-g-induced
STAT1 (Hartman et al., 2005).
The activation of NF-kB by type I IFNs is somewhat
controversial, but the differences seen in different labo-
ratories may be due to the different cell types that were
studied. In Daudi and some other cell types, type I IFN
was reported to signal to NF-kB through a pathway in-
volving PI3K and AKT (Yang et al., 2000, 2001). Electro-
phoretic mobility shift assays revealed increased DNA
binding of either p50-c-Rel or p50-p65. However, in fi-
brosarcoma cells, IFN-b does not induce any DNA bind-
ing activity but is required for phosphorylation of p65
and transcriptional induction of the CXCL11 gene (Rani
et al., 2002). IFN-b-induced activation of the p50-p65
complex of NF-kB is crucial for induction of the chemo-
kines MIP-1b and RANTES in primary human microglia,
but it is not clear whether this effect is dependent on up-
stream PI3K-AKT activation (Kim et al., 2002). In con-
trast, astrocytes do not activate NF-kB in response to
IFN-b and accordingly do not produce RANTES (Hua
and Lee, 2000). Interestingly, IFN-b promotes the sur-
vival of astrocytes by stimulating PI3K-AKT and down-
stream activation of yet unknown transcription factors
(Barca et al., 2003), in contrast to Daudi B cells (Yang
et al., 2001) and human neutrophils (Wang et al., 2003),
which depend on type I IFN-induced PI3K-AKT-NF-kB
or PI3K-PKC-d-NF-kB activation, respectively, for pro-
tection from apoptosis. Both the IFN-b-induced in-
crease of adhesion (Navarro et al., 2003) and soluble
IL-1Ra production in human monocytes (Molnarfi et al.,2005) depend on PI3K linked to an unknown transcrip-
tion factor and are STAT1 independent, but perhaps still
dependent on the activation of another STAT. These
data clearly show cell type-specific responses to type I
IFNs, involving the activation of PI3K plus NF-kB or
PI3K plus unknown transcription factors.
The IFN-b-induced activation of AP-1 in primary hu-
man microglia depends upon the activation of ERK,
which is also responsible for the phosphorylation of ser-
ine 727 of STAT1 (Kim et al., 2002). Inhibition of ERK sup-
pressed the induction of the chemokines MIP-1b, MIP-
1a, MCP-1, and RANTES by IFN-b in microglia, which
could depend on inhibition of AP-1 activation, STAT1-
S727 phosphorylation, or both. It is not yet known
whether AP-1 is activated in any other cell type besides
microglia, but it is likely to be cell type specific, just as is
the activation of NF-kB family members. More studies
are needed to reveal the details, and also whether the
activation of AP-1 is involved in the expression of IFN-
induced genes other than chemokines.
Interferon regulatory factor (IRF) family members also
play an important role in type I IFN-dependent signaling
pathways (see accompanying review by Honda et al.,
2006). For instance, IRF-9 directs the binding of ISGF3
to the core ISRE. IFN-a-dependent induction of IL-10
in B cells requires that both IRF-1 and STAT3 bind to
ISRE and GAS motifs in the promoter (Ziegler-Heitbrock
et al., 2003). However, IRFs by themselves, without the
help of any STAT, can also induce certain genes. Studies
of the human STAT1 promoter reveal that ISGF3 or
STATs 1–3 are not responsible for induction of this
gene by IFN-a, but that IRF-1 is (Wong et al., 2002). Other
examples of genes induced by type I IFNs only through
the binding of IRFs to ISREs in their promoters are those
that encode murine MHC class I, GBP, and b2M, and hu-
man IFN-ab and MxA (reviewed in Kanno et al., 2005).
IRF-4 and IRF-8 are immune cell-specific members of
the IRF family that regulate the development of myeloid,
lymphoid, and DCs. They can form heterodimeric com-
plexes with yet another immune cell-specific transcrip-
tion factor, namely PU.1-Spi-1, a member of the Ets fam-
ily (reviewed in Kanno et al., 2005). Notably, some type I
IFN-responsive genes are regulated by ISREs that have
an IRF-4- or IRF-8-PU.1 binding site, and are therefore
named Ets-IRF response elements (EIRE) (Meraro
et al., 2002). Examples of genes with EIRE are ISG15,
ISG54, and several other ISGs (reviewed in Kanno
et al., 2005). In nonimmune cells that do not contain
IRF-4, IRF-8, or PU.1, these classical ISGs are induced
by binding of other IRF members to the ISRE-EIRE (Mer-
aro et al., 2002). It is interesting that different cells em-
ploy different signaling strategies in response to type I
IFNs to activate the same ISGs. Therefore, the existence
of immune cell-specific transcription factors (IRF-4, IRF-
8, PU.1) explains why, for instance, ISG15 is so highly
induced by IFN-a and IFN-b in monocytes and lympho-
cytes (D’Cunha et al., 1996). In addition, many ISGs
that contain EIREs have a special role in immune cells.
Because of the ability of immune cells to respond in
this unique way to type I IFNs, it is important to under-
stand the mechanisms that underlie the formation of
IRF-4- or IRF-8-PU.1 complexes. Phosphorylation of
PU.1 occurs after LPS or IL-3 stimulation through a
casein kinase II- or p38 MAPK-dependent pathway,
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known about kinase pathways that regulate the phos-
phorylation of IRF-4, IRF-8, or PU.1 in response to
type I IFNs.
In addition to the inducible binding of transcription
factors as a result of activation by upstream kinases,
constitutive transcription factors are likely to play a
role in transcription induced by type I IFNs, and cell
type-specific differences in their expression may well
contribute to cell type-specific responses. The chroma-
tin-remodeling BAF complex is required for the maximal
induction of a subset of IFN-a target genes (Liu et al.,
2002). The ubiquitous transcription activator Sp1 inter-
acts with the BAF complex in vivo and augments BAF-
mediated activation of, for example, the IFITM3 pro-
moter. In the absence of the BAF complex, Sp1 binds
constitutively to the IFITM3 promoter, suggesting that
it may recruit or stabilize the BAF complex bound to
the promoter (Liu et al., 2002). It is not yet known
whether other constitutive transcription factors play a
role in ISG induction.
STAT-Independent Signals
The amount of IRF-9, a component of the ISGF3 com-
plex, is increased after stimulation with either IFN-g or
type I IFN. Analysis of the murine IRF-9 promoter re-
vealed a unique IFN-g-activated response element
called GATE (Kalvakolanu, 2003). In response to IFN-g,
two factors bind to GATE: one is the CCAAT/enhancer
binding protein C/EBP-b and the other is the GATE bind-
ing factor GBF-1 (Kalvakolanu and Roy, 2005). By means
of chemical inhibitors and dominant-negative mutants,
it has been shown that ERK1, ERK2, and MEK1 are the
upstream kinases needed to activate C/EBP-b in re-
sponse to IFN-g. In the case of type I IFNs, the activation
of transcription factors other than STATs is necessary to
induce IRF-9. Even though type I IFNs failed to activate
STAT1, STAT2, and STAT3 in FF cells, IRF-9 was still
induced by IFN-b in these cells (Rani and Ransohoff,
2005). Activation of PI3K-AKT-NF-kB and ERK-AP-1 by
type I IFNs are other examples of signaling pathways
that operate independently of the classical JAK-STAT
pathway.
IFN-b cannot increase IRF-9 expression in STAT1-de-
ficient cells, suggesting that, although activated STAT1
is not necessary, unphosphorylated STAT1 may be re-
quired (Rani and Ransohoff, 2005). Likewise, in STAT1-
deficient cells, IFN-g fails to activate ERK1 and ERK2,
whereas restoration of STAT1 restores ERK1 and ERK2
activation (Kalvakolanu, 2003). As shown by Chatter-
jee-Kishore et al. (2000) and Yang et al. (2005), unphos-
phorylated STAT1 and STAT3, induced in response to
IFN-g or gp130-linked cytokines, respectively, induce
sets of genes quite distinct from those that respond to
phosphorylated STAT1 and STAT3. Further research is
needed to discover which kinases and transcription
factors are required for the transcriptional induction of
IRF-9 by IFN-b and how unphosphorylated STAT1
contributes.
Signaling Responses of Different Blood Cell Subsets
and Variability among Individuals
Macroarray analysis of IFN-a2a-stimulated genes in pe-
ripheral blood mononuclear cells, T cells, DCs, and fi-brosarcoma, hepatoma, and T cell lymphoma cell lines
reveal marked cell type-specific and donor-specific dif-
ferences in the spectrum of ISGs induced (Schlaak et al.,
2002). There are also many quantitative differences. Of
the 150 genes studied, IRF-7 was identified as the only
one exclusively induced in hematopoietic cells. In DCs,
42 different genes are induced and 60% of these are up-
regulated in all three donors studied. In contrast, only
22% of the genes induced in T cells (45 in total) are
enhanced in all five donors studied, indicating that the
donor-specific differences are more prominent in T cells
than in DCs (Schlaak et al., 2002). A different study of
IFN-a2-induced genes in DCs and T cells, with the
same macroarrays, shows thatCXCL10 andNOS2A (en-
coding iNOS) are uniquely induced by IFN-a2 in DCs but
not in T cells (Hilkens et al., 2003). IL12RB2 is an example
of a gene induced only in T cells. If arrays containing the
whole human genome had been used in these studies,
more cell type-specific genes would surely have been
identified. We propose that several factors can contrib-
ute to these effects: for example, differences in the bind-
ing of constitutive transcription factors that are ex-
pressed differentially in different cell types, differential
STAT activation, and differential activation of transcrip-
tion factors other than STATs can all contribute to the dif-
ferential induction of ISGs by type I IFNs in different cell
types. In addition, priming may well play a role. It is inter-
esting that Schlaak et al. (2002) observe far more varia-
tion in response to IFN-a in T cells than in DCs, perhaps
because naive, resting T cells respond differently to type
I IFNs than do activated, effector T cells (Dondi et al.,
2003; Van De Wiele et al., 2004). From all of the above
studies, it is clear that different types of blood cells
activate quite distinct signaling pathways in response
to type I IFNs and that these differences are likely to ac-
count not only for cell type specificity and donor specific-
ity but also for different subtype-specific responses to
the various type I IFNs.
Conclusion and Perspective
We propose that different patterns of STAT activation in
different cells contribute to the activation of ‘‘STAT-only
genes.’’ In addition to activation of JAKs, other kinases
such as PI3K, p38, ERK, and JNK become activated
and can contribute to the serine phosphorylation of
STATs. In addition, these kinases (and others yet to be
identified) are likely to lead to the activation of transcrip-
tion factors other than STATs (e.g., NF-kB, AP-1, IRF-1,
IRF-4, IRF-8, PU.1). Additional signaling pathways could
either collaborate with STATs at the promoter level and
contribute to the activation of ‘‘STAT + transcription fac-
tor (TF) genes’’ or function totally independent of any
STAT, and thus lead to the activation of ‘‘TF-only genes’’
(Figure 1). Furthermore, the differential activation of TFs
other than STATs by kinases other than JAKs is not only
likely to be an important aspect of cell type specificity
but also a major cause of differential gene activation
by type I IFN subtypes. Therefore, depending on which
combinations of STATs and TFs eventually become ac-
tivated in each cell type, type I IFN can promote either
survival and proliferation or apoptosis and growth inhi-
bition, function as a negative regulator of development
(B cells, osteoclasts), or function as an important modu-
lator of T cells and NK cells by enhancing IFN-g
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368Figure 1. The Complexity of Type I IFN-Dependent Signaling Helps to Explain Cell Type Specificity, IFN Subtype Specificity, and Individual
Variability in Responses
See the Conclusion and Perspective section for a description of the details.production and cytotoxic effector functions. Priming
with a cytokine (for example, IFN-g, IL-1b, IFN-b) can ei-
ther positively (by increasing STAT amounts, Syk activ-
ity, or receptor crosstalk) or negatively (through PTPs)
influence the tyrosine phosphorylation and activation
of STATs. More importantly, priming results in increased
or decreased activation of specific STATs, and thus is
likely to have a major impact eventually on which
‘‘STAT-only genes’’ or ‘‘STAT + TF genes’’ will be in-
duced. We propose that priming is a major cause of
altered type I IFN-dependent signaling in different indi-
viduals. We hope that the model of Figure 1 provides a
framework for understanding the complex modulation
of type I IFN-dependent signaling, but much is still to
be learned. Individual cell subsets need to be studied
in order to understand why certain STATs are preferen-
tially activated and whether all subsets are equally sus-
ceptible to priming in response to certain cytokines.
Also, the activation of kinases other than JAKs in each
individual cell type need to be linked to the activation
of TFs other than STATs, and eventually to the induction
of specific genes. More research is also needed to iden-
tify relevant cis-acting elements in the promoters of
‘‘STAT + TF genes’’ and ‘‘TF-only genes.’’ All this infor-
mation will help us to understand fully how different in-
dividuals and different cell types react to the different
type I IFN subtypes during infection and inflammation.
Because IFN-a2 and IFN-b are used to treat several can-
cers and multiple sclerosis, such data are also crucial
to help identify specific mechanisms that could lead to
improved treatment, since these treatments are unfortu-
nately not effective in all patients.Acknowledgments
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